SLU-PP-332: ERR research and the tablet label

What the ERR study investigates

A 2023 paper examined a synthetic agonist of estrogen-related receptors ERRα, ERRβ and ERRγ in preclinical models. Findings included metabolism-related gene programmes and experimental functional measurements. [1]

Preclinical findings and product format

The experimental design determines what can be concluded. Cell and animal findings do not justify an efficacy promise for a tablet sold in a catalogue. In particular, an experimental exposure route does not establish oral availability of a particular formulation.

Reading 500 mcg per tablet

The bottle contains 100 tablets with a nominal 500 mcg each. Arithmetically, this is 0.5 mg per tablet and 50 mg total per bottle. This calculation describes content rather than giving use instructions or stating absorbed content.

Tablets need their own quality data

Alongside compound identity, content uniformity, excipients and tablet stability matter. Purity data for an ingredient do not automatically establish the properties of every finished tablet. Suitable testing of the finished product is needed.

Sources & context

1. Synthetic ERR agonist: experimental exercise-related response (2023)

Sources concern the models and preparations investigated, rather than a particular shop batch. Research products are intended exclusively for laboratory research, not for human use.